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PP-059 Rifaximin salvage therapy for
metronidazole-resistant Clostridium difﬁcile
infection – a prospective pilot trial
P. Patrick Basu*,1,2, Amreen Dinani 1, Krishna Rayapudi 3,
Tommy Pacana3, Niraj James1. 1New York Hospital Queens,
Flushing, New York, USA; 2Columbia University College of
Physicians and Surgeons, New York, New York, USA; 3Forest Hills
Hospital, Forest Hills, New York, USA
Background: C. difﬁcile infection (CDI) is a recent epidemic in
the United States affecting all age groups. Resistance to metron-
idazole has become a clinical challenge that warrants the use
of salvage therapy. We evaluated the efﬁcacy of rifaximin in
metronidazole-resistant CDI in the community.
Methods: Twenty ﬁve patients with CDI were recruited. Age
range: 48-65 years; male - 13, female - 12; community-acquired
CDI-13, nursing home-acquired CDI-12; mean white blood cell
count-14,000/mm3, mean creatinine-0.9 mg/dL. All had mild-to-
moderate CDI (5-10 bowel movements a day). Within the last
3 months, all were exposed to antibiotics, 18 (72%) to proton
pump inhibitors, and 12 (48%) hospitalized. All CDI was resis-
tant to metronidazole. All received oral rifaximin 400 mg three
times daily for 14 days after stopping metronidazole. After 56
days, stool was tested for C difﬁcile using PCR (Quest Diag-
nostics, Teterboro, NJ) to assess the efﬁcacy of treatment. Ex-
clusions included sepsis, abdominal distention, leukocyte count
>20,000/mm3, human immunodeﬁciency virus infection, multi-
organ failure, renal failure, recent exposure to vancomycin
or rifampicin, recent organ transplant recipients, patients on
ventilator support, and receiving chemotherapy.
Results: Sixteen (64%) patients eradicated the infection (nega-
tive PCR after 56 days). Three (12%) aborted therapy because
of abdominal distention. In a per-protocol analysis, 72.7% of
patients responded to rifaximin salvage therapy. Oral rifaximin
was well tolerated.
Conclusion: Rifaximin may be considered in the treatment of
mild-to-moderate metronidazole resistant CDI. Larger random-
ized trials might support these preliminary ﬁndings.
PP-060 Prevalence and antimicrobial susceptibility of
Campylobacter spp. isolated from beef and raw
chicken in Tehran, Iran
Maryam Sanaie, Mohammad Hamidian*, Masoumeh Azimi-Rad,
Mehdi Bolﬁon, Mohammad Reza Zali. The Research Center for
Gastroenterology and Liver Disease, Shaheed Beheshti
University of Medical Sciences, Tehran, Iran
Background: Campylobacter spp. resistant to commonly used
antimicrobials constitute one of the leading causes of bacterial
gastrointestinal worldwide. The current study was done to deter-
mine prevalence and antimicrobial resistance of Campylobacter
spp. from retailers in Tehran.
Methods: During 2007-2008, samples of beef and raw chicken
were randomly selected from retailers in Tehran and cultured and
identiﬁed according to biochemical and microbiological standard
methods. Antimicrobial susceptibility testing of the isolates was
done by Kirby–Bauer method for ampicillin, neomycin, strepto-
mycin, nalidixic acid, gentamicin, tetracycline, spectinomycin,
chloramphenicol, and ciproﬂoxacin.
Molecular identiﬁcation of the isolated was done using PCR by
speciﬁc primers for hippuricase gene for C. jejuni and aspartoki-
nase of C. coli as previously described.
Results: A total of 378 samples obtained of which 188 (49.7%)
were raw chicken and 190 (50.2%) were beef. Campylobacter
spp. were collected from 112 (29.6%) of the cultured samples. Of
these 75% were C. Jejuni and 25% C. coli. The majority of the iso-
lates (71.6%) were resistant to nalidixic acid while none of them
showed resistance to gentamicin and imipenem. Resistance to
ciproﬂoxacin, tetracycline ampicillin and neomycin were 47.4%,
27.4%, 23.2% and 3.2% respectively and 2.1% of the isolates were
resistant to streptomycin and spectinomycin.
Conclusion: The results showed a high prevalence of resistance
to nalidixic acid and ciproﬂoxacin emphasizing to continuous
resistance monitoring of Campylobacter spp. in the country.
Because of the rapid dissemination of resistance genes and an-
tibiotic pressure, a prudent use of antibiotics is imperative to
preserve its usefulness in the country.
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PP-061 Viral factors have little or no inﬂuence on liver
injury in CHB: observation from Bangladesh
Mamun Mahtab*,1,2, Salimur Rahman1,2, Mobin Khan1,
Mohammad Kamal1, Rakesh Aggarwal3, Sirish Kumar3,
Fazle Akbar4. 1Bangabandhu Sheikh Mujib Medical University;
2Viral Hepatitis Foundation Bangladesh; 3Sanjay Gandhi
Post-graduate Institute of Medical Sciences; 4Toshiba General
Hospital
Background: It is assumed that patients with CHB with high
DNA exhibit increased liver damage and treatment guidelines
emphasize on reducing viral load. These observations are from
developed countries, but little is known about >80% HBsAg carri-
ers living in developing nations. In this study, we addressed this
issue.
Methods: 402 Bangladeshi CHB patients were enrolled and tested
for HBV serologic markers and ALT. All underwent liver biopsy.
HBV genotyping was done in 45.
Result: High HBV DNA (>100,000 copies/ml) was detected in
64.4%. 43.5% were HBeAg +ve and 56.5% HBeAg -ve. HAI-NI ≥3
was in 62.9% HBeAg +ve and 49.8% HBeAg -ve respectively. In
high HBV DNA, 59.8% had higher HAI-NI, opposed to 45.5% with
low DNA. Much more with low DNA had considerable hepatic
ﬁbrosis compared to high DNA. However difference in HAI-F was
not signiﬁcant. Genotyping was done in 45. Genotype C (38%) and
D (49%) were predominant. Comparison between HBV genotype,
DNA load and liver damage could not be done because genotyping
was done in only 45.
Conclusion: Correlation could not be established between viral
load and liver damage in CHB in Bangladesh. Further study is
needed to identify other factors inﬂuencing liver damage in
CHB in developing nations. Our study may suggest the research
direction for management of these cases.
PP-062 Effects of methylprednisolone and tacrolimus on
cccDNA replication of hepatitis B virus in
HepG2.2.15 cell line
Weiping Zheng*, Hongli Song, Zhongyang Shen. Department of
Organ Transplantation, Tianjin the First Central Hospital
Aim: The effect of Methylprednisolone (MP) and tacrolimus
(FK506) on hepatitis B virus (HBV) replication was investigated,
and level of cccDNA after MP and FK506 treatment was studied
in order to provide clues to explore the effect of MP and FK506
on HBV replication.
Methods: MTT assay was used to evaluate the cytotoxicity of
MP and FK506. The HBV replication level in HepG2.2.15 cell
line was determined by an electrochemiluminescence analysis
of hepatitis B surface antigens (HBsAg) and Hepatitis B e anti-
gens (HBeAg) in culture supernatant, while the intracellular HBV
cccDNA replication level was analyzed by real time polymerase
chain reaction (RT-PCR).
Results: MTT method conﬁrmend that the nontoxic concentra-
tions of MP and FK506 were 0-500uk/ml. After the treatment
of MP at the concentration of 0, 5, 10, 20, 50, 100, 250 and
500 μg/L, in comparison to the control group. MP was able to
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inhibit the expression of HBsAg, HBeAg, and HBV DNA replication
in vitro in a dose-dependent manner. A RT-PCR analysis indicated
that the expression of cccDNA changed signiﬁcantly in the MP
treatment group compared to the control group and in a dose
and time-dependent manner. FK506 did not the same role in
the levels of HBVDNA and cccDNA. However, FK506 at different
nontoxic contrations showed no signiﬁcant inhibitory effect on
the levels of HBsAg HBeAg and HBVDNA.
Conclusion: Our study identiﬁed MP does- and time-dependently
inhibits the HBV replication in vitro, and found that cccDNA for
this inhibitory effect. FK506 does not exercise similar effects.
PP-063 NOTCH 1 regulates FOXP3 regulatory T cells and
deranged TGF-β signaling in progressive stages of
hepatitis B infection
Nirupama TrehanPati *,1, Shikha Shrivastav2, Dinesh
Mani Tripathy2, Sukriti Baweja2, Ketki Dongre2, Hissar Syed2,
Shiv Sarin1,2. 1Institute of Liver and Biliary Sciences, New Delhi,
India; 2G.B. Pant Hospital, New Delhi, India
Objectives: Notch receptors are implicated in modulating the
differentiation of antigen speciﬁc T cells to regulatory T cells.
TGF-β as a key mediator, acts synergistically with regulatory
cells. Our objective was to study the expression of Notch 1,FOXP3
and TGF-β signaling in PBMCs, liver inﬁltrated lymphocytes in pa-
tients with HBV infection.
Methods: Patients with chronic hepatitis B (CHB) (n=10) (age
29.4±13.2 yr., M:F=8:2), HBV cirrhosis (n=8) (age-45.6±12 yr.
M:F=2:1) and liver biopsies from normal liver (n=8) (age 49±3.8
yr. M:F=3:1) were studied. PBMCs and LIL were isolated from
blood and liver tissues. Percentages of regulatory T cells with
Notch expression were analyzed by FACS Analysis. mRNA expres-
sion of Notch1, HES1, Jagged1, TGF-β, STAT1, SMAD3 and SMAD4
genes was analyzed by quantitative RT-PCR in PBMCs, LIL and
biopsies.
Results: There was a signiﬁcantly higher co-expression of Notch1
and the percentages of NOTCH1/FOXP3 (50.4% vs.3.72 and 2%)
(p=0.05) in liver inﬁltrated lymphocytes of cirrhotic patients than
peripheral blood. Expression of TGF-β, STAT1, SMAD3 and SMAD4
in cirrhotic LIL was signiﬁcantly 2-3 folds lower than PBMCs. In
chronic HBV biopsies, expression of TGF-β, STAT1, SMAD3 and
SMAD4 was 4-6 folds higher than in normal liver biopsies.
Conclusion: We showed that higher expression of Notch1 and
FOXP3 expression in liver inﬁltrated lymphocytes may have
differentiated induced regulatory T cells. However, decreased
expression of TGF-β and its downstream signaling molecules in
LILs may be responsible for loss of its regulatory cells suppressive
ability.
PP-064 A tenofovir therapy HBV mathematical model for
HBeAg negative and positive patient
Man Li, Yongmei Su*. Applied Science School, University of
Science and Technology Beijing, Beijing
Background: HBeAg negative and HBeAg positive patients are
different in the HBV replication rate. Based on P.Marcellin et al’s
clinical data and the HBV infection dynamic model proposed by
Nowak et al. we set up a Tenofovir therapy model for HBeAg
negative and positive, which have good agreement with above
clinical data.
Methods: A model of HBV is described by four variables: x, y,
v, z represent uninfected cells, infected cells, free virus, and
immune cells. The model include 10 parameters: λ, d, b, a, p, k,
u, k2, k3, k4 where the meanings of λ, d, b, a, p, k, u are the
same as those given in Nowak’s model, k2 represents the curative
effect, k3, k4 are relevant to the immune, we choose {λ, d, b,
a, p, u, k3, k4 = 4.621e5, 6.9e-3, 6.508e-4, 6.9e-3, 0.058, 0.35,
0.95, 0.036}
For HBeAg positive and negative, we chose k=5, k2=4.85, and k=2,
k2=1.98 respectively, which reﬂect the different HBV replication
rate between HBeAg positive and negative patient.
Results: The simulation data of our model are qualitatively
agreement with the HBeAg positive and negative clinical data
during the treatment with Tenofovir.
Conclusion: The discrepancy between HBeAg negative and posi-
tive were reﬂected through different parameters by our model,
which shows our model may possibly capture the dynamics of
anti-HBV infection treatment with Tenofovir.
Acknowledgment: This work is jointly supported by the11-5 Key
Special Project of China (No. 2008ZX10502) and the NNSF of
China (No. 0674059).
PP-065 Therapeutical effect of Ademetionine
(Transmetil) for chronic cholestasis diseases
Wen Xie*, Yan-Bin Wang, Wei-Ni Ou. Beijing Ditan Hospital
Objective: To evaluate the efﬁcacy and safety of different
dosage of Ademetionine (Transmetil) in different cholestasis
diseases.
Methods: It’s a retrospective study, 56 cases who treated with
Ademetionine (Transmetil) were assigned to 1g/d and 2g/d by
the dosage they used. There is no statistic difference between
the two groups in age, height, body weight, heart rate, blood
pressure and sex ratio (P>0.05). The levels of ALT, AST, TBiL,
DBiL, GGT and TBA before treated and 2 weeks after treated of
both groups were observed.
Results: After 2 wk of treatment, the levels of ALT, AST, TBiL,
DBiL, GGT and TBA were reduced signiﬁcantly (p=0.001, 0.002,
0.029, 0.01, 0.002, 0.002 P<0.05) compared with those before
treatment, but the reduced levels of ALT, AST and GGT had no
marked difference between the two groups (p=0.055, 0.14, 0.774
P>0.05). And the reduced levels of TBiL, DBiL and TBA were
signiﬁcantly different between the two groups (p=0.025, 0.038,
0.039 P<0.05). No severe adverse reactions were found in both
groups.
Conclusions: Ademetionine (Transmetil) has obvious effect on
Cholestasis diseases, and the treatment of dosage 2g/d has more
effective in reduce TBiL, DBiL and TBA than that of 1g/d. It’s
safe in both dosage groups.
PP-066 Effect of adeforvir dipivoxil on HBcAg-speciﬁc
cytotoxic T cells in patients with chronic
hepatitis B
Jie Yan1, Wen Xie*,1, Yahui Lin2, Xin Feng1, Beibei Wang1,
Jiang Xiao1, Weini Ou1, Yangbin Wang1, Jun Cheng1. 1Beijing
Ditan Hospital; 2Chinese Academy of Medical Sciences
Background:To study the effect of adeforvir dipivoxil on HBcAg-
speciﬁc cytotoxic T cells in patients with chronic hepatitis B
(CHB).
Methods: Frequency of circulating HBcAg-speciﬁc cytotoxic T
cells from 11 HLA-A2+ patients with chronic hepatitis B were
studied longitudinally before and after adeforvir dipivoxil ther-
apy by HLA-A2/peptide tetramer staining.
Results: Frequencies of HBcAg-speciﬁc cytotoxic T cells were
no signiﬁcant differences between before and after adeforvir
dipivoxil therapy.
Conclusion: There is probably no effect effect of adeforvir
dipivoxil on HBcAg-speciﬁc cytotoxic T cells in patients with CHB.
PP-067 Effects of interventional therapy for primary liver
carcinoma on the liver function of patients
Wei Ji *. Beijing You-an Hospital
Background: The effects of interventional therapy for hepato-
